Restructuring
Enorama Pharma Calls December 4 Meeting to Weigh Liquidation or Continued Operations
By News Desk ·
Key takeaways
- Enorama Pharma will hold an extraordinary general meeting on December 4, 2026 in Malmö to decide whether to continue operations or go into liquidation.
- The board primarily proposes continued operations after a second balance sheet for liquidation purposes showed equity fully restored to SEK 24,006,297.
- DS Global Pte. Limited, which holds about 29.81 percent of Enorama Pharma, would see a 9 percent annual interest rate introduced on its USD 2.5 million loan from December 4, 2026.
- Micael Karlsson, attorney-at-law at Advokatfirman Delphi, is proposed as chairman of the meeting.
Enorama Pharma AB (publ) has summoned shareholders to an extraordinary general meeting on December 4, 2026, at which they will decide whether the company continues its operations or goes into liquidation, the company said in a notice published via news.cision.com. The board primarily proposes continued operations, with liquidation as a secondary alternative.
Enorama Pharma's December 4 Agenda
The meeting opens at 10.00 at Advokatfirman Delphi's premises at Skeppsbron 4B in Malmö. Shareholders must be registered in the share register kept by Euroclear Sweden AB as of the record date of November 26, 2026, and must notify the company of their participation no later than November 30, 2026. The board proposes that Micael Karlsson, attorney-at-law at Advokatfirman Delphi, be appointed chairman of the meeting.
One agenda item concerns a loan agreement the company entered into with DS Global Pte. Limited on November 13, 2026, under which the lender makes USD 2,500,000 available. The loan runs up to and including December 31, 2027, and is interest-free. DS Global and Enorama Pharma now wish to introduce an annual interest rate of nine percent under the agreement, which the company describes as market terms. If approved, interest starts accruing from December 4, 2026. DS Global, together with companies under common control, holds approximately 29.81 percent of the shares and votes in Enorama Pharma, making the company an associate and the interest introduction a related party transaction. A valid resolution requires support from shareholders representing more than half of the votes cast, with DS Global's shares and votes excluded.
The liquidation item stems from an extraordinary general meeting, also serving as the initial meeting for liquidation purposes, held on April 7, 2026, at which shareholders resolved that operations should continue. Under the Companies Act (2005:551), a second meeting for liquidation purposes must be held within eight months of the initial meeting. The board has prepared a new balance sheet for liquidation purposes, reviewed by the company's auditor, and will present it at the meeting. The board primarily proposes continued operations, stating that the balance sheet shows equity fully restored with no capital deficiency. As a secondary alternative, the board proposes liquidation, effective from the date the Swedish Companies Registration Office appoints a liquidator.
Enorama Pharma's Restored Equity
According to akta.pro company records, the April 7, 2026 meeting resolved to continue operations rather than pursue liquidation, with the board committing to restore equity within eight months through a capital injection from existing and new investors. The same records show negative equity of SEK -25,559,465 as of March 2026, less than half of registered share capital of approximately SEK 11.65 million. The company's notice states that the New Loan Agreement, together with the Amendment Agreement, increases shareholders' equity to SEK 24,006,297.
Enorama Pharma's Liquidation Timeline
Under the board's secondary proposal, a liquidation resolution would take effect from the date the Swedish Companies Registration Office appoints a liquidator. The board's preliminary assessment is that distribution of the company's remaining assets would occur within seven to twelve months after that decision, with proceeds to shareholders conservatively estimated at SEK 0 per share. The board intends to supplement its proposal with a proposed liquidator.